Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LMB-9
- Development stage
- Phase 1
- Lead developer
- National Cancer Institute
- Modality
- Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
LMB-9 is a recombinant disulfide-stabilized anti-Lewis Y IgG immunotoxin. It consists of an antibody that specifically targets the Lewis Y antigen, which is commonly expressed on the surface of certain tumor cells, conjugated to a 38 kDa toxic element derived from *Pseudomonas aeruginosa* exotoxin A. The mechanism of action involves binding to Lewis Y-positive tumor cells and delivering the toxin intracellularly, leading to cell death. LMB-9 has been investigated primarily for its potential in treating advanced adenocarcinomas such as those of the colon, rectum, pancreas, and esophagus.
- Other names
- LMB-9 immunotoxinLMB9 immunotoxinLMB 9 immunotoxin
02
Targets
EEF2 (Eukaryotic elongation factor 2)LeY (Lewis Y antigen)
Beyond the preview
Go deeper on LMB-9.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LMB-9.